Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
about
Insights into the key roles of proteoglycans in breast cancer biology and translational medicinePrognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.Targeting syndecans: a promising strategy for the treatment of cancer.The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumorsSyndecans as modulators and potential pharmacological targets in cancer progression.Tumor Grade versus Expression of Invasion-Related Molecules in Astrocytoma.Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis.Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.Cancer Cell Glycocalyx and Its Significance in Cancer Progression
P2860
Q28085548-6ADB0CC7-CC57-4EA3-B728-B190580AE58FQ36769318-C8BFE15E-9591-4C28-B1B9-EAD39C948A86Q36947703-70A1D0B7-C5AB-4656-A676-86827DBF4779Q37422972-AED6FF53-F4DD-4AA1-8437-6B2E09A84F44Q37525296-C542DA2E-AC3E-4D7D-8ACA-D2EC397E1D4AQ38082795-29E66B79-8EED-4FEF-8B8B-BE19F44AA26CQ38176008-5EFE21A5-40A9-4B2E-A1AD-B45B42128452Q38189392-191856F4-6D1B-448C-B562-D4036EC66FD8Q38761444-4A2C158E-A440-41FE-94F6-01A4C691EEA7Q39351138-2473BBB8-774F-4BA9-9A4D-5176B3C45DFDQ40208474-9468E2A6-6F7B-4B62-945F-D11DE9738081Q46059085-E2AFB990-4E05-475C-A98A-F5CB239A5E92Q51372167-671FACE0-0272-4738-9016-AEC07F62A58CQ55250705-27713D03-FBD5-4948-B1EB-2DEB49F0F5BCQ57168005-9085999C-F26A-4BED-B802-E6DE7130ADF4
P2860
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@ast
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@en
type
label
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@ast
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@en
prefLabel
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@ast
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@en
P2093
P2860
P50
P356
P1433
P1476
Syndecan-1 antigen, a promisin ...... on MDA-MB-468 xenograft tumors
@en
P2093
Anne Lise Ruellan
Caroline Rousseau
François Davodeau
John Wijdenes
Karine Bernardeau
Michel Chérel
Sebastien Gouard
P2860
P2888
P356
10.1186/2191-219X-1-20
P50
P577
2011-09-01T00:00:00Z
P6179
1046579495